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BACKGROUND: Recent clinical trials of new glucose-lowering treatments 
have drawn attention to the importance of hospitalization for heart failure 
as a complication of diabetes mellitus. However, the epidemiology is not 
well described, particularly for type 1 diabetes mellitus. We examined the 
incidence and case-fatality of heart failure hospitalizations in the entire 
population aged ≥30 years resident in Scotland during 2004 to 2013.
METHODS: Date and type of diabetes mellitus diagnosis were linked 
to heart failure hospitalizations and deaths using the national Scottish 
registers. Incidence rates and case-fatality were estimated in regression 
models (quasi-Poisson and logistic regression respectively). All estimates 
are adjusted for age, sex, socioeconomic status, and calendar-year.
RESULTS: Over the 10-year period of the study, among 3.25 million people 
there were 91 ,429, 22 959, and 1313 incident heart failure events among 
those without diabetes mellitus, with type 2, and type 1 diabetes mellitus, 
respectively. The crude incidence rates of heart failure hospitalization were 
therefore 2.4, 12.4, and 5.6 per 1000 person-years for these 3 groups. 
Heart failure hospitalization incidence was higher in people with diabetes 
mellitus, regardless of type, than in people without. Relative differences 
were smallest for older men, in whom the difference was nonetheless large 
(men aged 80, rate ratio 1.78; 95% CI, 1.45–2.19). Rates declined similarly, 
by 0.2% per calendar-year, in people with type 2 diabetes mellitus and 
without diabetes mellitus. Rates fell faster, however, in those with type 1 
diabetes mellitus (2.2% per calendar-year, rate ratio for type 1/calendar-
year interaction 0.978; 95% CI, 0.959–0.998). Thirty-day case-fatality was 
similar among people with type 2 diabetes mellitus and without diabetes 
mellitus, but was higher in type 1 diabetes mellitus for men (odds ratio, 
0.96; 95% CI, 0.95–0.96) and women (odds ratio, 0.98; 95% CI, 0.97–
0.98). Case-fatality declined over time for all groups (3.3% per calendar-
year, odds ratio per calendar-year 0.967; 95% CI, 0.961–0.973).
CONCLUSIONS: Despite falling incidence, particularly in type 1 diabetes 
mellitus, heart failure remains ≈2-fold higher than in people without 
diabetes mellitus, with higher case-fatality in those with type 1 diabetes 
mellitus. These findings support the view that heart failure is an under-
recognized and important complication in diabetes mellitus, particularly 
for type 1 disease.
© 2018 The Authors. Circulation is 
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access article under the terms of the 
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Recent clinical trials of new glucose-lowering treat-ments have drawn attention to the importance of hospitalization for heart failure as a complication 
of diabetes mellitus.1–4 However, little is known about 
the epidemiology of heart failure in unselected individ-
uals with type 2 diabetes mellitus, and even less about 
those with type 1 diabetes mellitus.
We have examined the incidence of heart failure for 
an entire country, and how this has changed over time. 
All residents in Scotland receive care from the National 
Health Service (NHS) which is free at the point of con-
tact. All diabetes mellitus–related community (primary 
care) and hospital outpatient encounters in Scotland 
are recorded in a centrally-accessible database, and 
these are linked to national hospitalization and mortal-
ity records. Given the prognostic import of developing 
heart failure, we have also investigated the case-fatality 
related to incident heart failure hospitalization and how 
this has changed over time.
Specifically, we examined the incidence rate for 
heart failure hospitalization and 30-day case-fatality af-
ter heart failure hospitalization over a 10-year period 
from January 2004 to December 2013 among people 
with diabetes mellitus (type 1 and type 2).
METHODS
Access to Data and Methods
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. However, 
individual-level data are available via application to NHS 
Information Services Scotland,5 aggregate data are pro-
vided in the supplemental appendix (Tables I and II in the 
online-only Data Supplement), and analysis code has been 
posted online.6
Datasets
We used data from the population-based Scottish diabetes 
mellitus register linked to national hospitalization and death 
records. The Scottish diabetes mellitus register is derived from 
primary and secondary care records for people with diabe-
tes mellitus diagnosed in normal clinical practice using blood 
glucose measurements or hemoglobin A1c with coverage of 
>99% since 2004,7 the start of the study period.
Anyone alive in Scotland aged 30 and older at any time 
from 2004 to 2013 was included in the analyses.
Definition of Heart Failure
Heart failure was identified from the first mention in any 
position (primary or secondary diagnoses) in hospital inpa-
tient records using codes from the ninth (ICD-9) and tenth 
(ICD-10) International Classification of Diseases revisions 
(402, 402, 402.1, 402.2, 402.4, 402.6, 402.9, 425.5, 428, 
428, 428.1, 428.9 and I11.0, I13.0, I13.2, I42.6, I50.0, I50.1, 
I50.9, respectively). Outpatient attendances with heart failure 
are not recorded in the Scottish national healthcare database, 
nor in the Scottish diabetes mellitus register.
Diabetes Mellitus Status and Diagnosis 
Date
Date and type of diabetes mellitus were obtained from the dia-
betes mellitus register based on the clinician-recorded date of 
diagnosis. Diabetes mellitus status was defined as type 2 diabe-
tes mellitus, type 1 diabetes mellitus and no diabetes mellitus.
Covariates
Age at first heart failure hospitalization and sex were 
identified from hospital admission and mortality records. 
Socioeconomic status was assessed via an area-based mea-
sure of deprivation which is assigned to residents of Scotland 
on the basis of where they live using the Scottish Index of 
Multiple Deprivation (SIMD).8 SIMD 2009 combines 31 indi-
cators across 7 domains: income, employment, health, edu-
cation, housing, geographic access, and crime. The index is 
generated from a weighted sum of the 7 domain scores for 
each area defined by postcodes (zip codes) which contain a 
median of 769 people. SIMD data were missing for approxi-
mately 1% of hospital admissions or death records, and these 
records were excluded from the analysis.
Clinical Risk Factors
As an additional analysis, to explore the association between 
demographic and clinical risk factors and subsequent risk of 
heart failure admissions, we also identified a closed cohort 
from the Scottish Diabetes Register. All patients in this cohort 
had been diagnosed with type 1 or type 2 diabetes mellitus 
on or before October 1, 2013 and had not had a heart failure 
admission in the 10 years before this date. Follow-up data 
were available for 3 years.
Heart failure in the closed cohort was defined as per 
the main analysis. However, the clinician-recorded diabetes 
mellitus type was corrected through the use of additional 
clinical information (eg, medication use) as described in a 
previous publication.9
Clinical Perspective
What Is New?
• Heart failure incidence has fallen over time for peo-
ple with and without diabetes mellitus, but is ≈2 
times higher in people with diabetes mellitus than 
people without diabetes mellitus.
• Heart failure case-fatality is higher in people with 
type 1 diabetes mellitus.
• Duration of diabetes mellitus and glycated hemo-
globin was associated with increased risk of heart 
failure in type 1 and type 2 diabetes mellitus.
What Are the Clinical Implications?
• Clinicians should be aware of the importance 
of heart failure in diabetes mellitus, especially 
in type 1 diabetes mellitus, where this risk is 
underappreciated.
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For this cohort, baseline characteristics such as glycated 
hemoglobin, body mass index, duration of diabetes mellitus, 
blood pressure, and retinopathy were also obtained from the 
diabetes mellitus register, taking the mean (or mode) of all 
measures not more than 3 years before the start date. Data 
on current prescriptions for selected drug classes (Table III 
in the online-only Data Supplement) were also obtained, as 
were data on previous stroke and myocardial infarction within 
the previous 10 years.
Statistical Analysis
Hospitalizations and Deaths
Using the population-based Scottish diabetes mellitus regis-
ter, linked to national hospitalization and death records, heart 
failure hospitalizations from January 1, 2004 (or the date at 
which each person was diagnosed with diabetes mellitus, if 
this occurred during the study period) to December 31, 2013 
were identified for people with diabetes mellitus aged 20 
to 89 years. Heart failure hospitalizations were defined as 
incident if these were the first to occur on or after January 
2004 where no previous heart failure hospitalization had 
been recorded during the preceding 10 years (Figure I in the 
online-only Data Supplement). As with our previous analyses 
we used a fixed period to define incident cases to avoid bias 
from nonobservation of prevalent cases.10 This analysis was 
replicated using the entire national hospitalization and death 
record to identify heart failure hospitalizations for the general 
adult population. Incident hospitalizations were summed by 
calendar year, age, sex, deprivation decile, and, for the diabe-
tes mellitus dataset, diabetes mellitus type. Within the levels 
of these stratifying variables, the number of incident heart 
failure hospitalizations in people without diabetes mellitus 
was derived by subtracting the diabetes mellitus heart fail-
ure hospitalizations from the general population heart failure 
hospitalizations.
Case-fatality was examined at 30 days, defined as the pro-
portion of patients who died from any cause within 30 days 
of any heart failure hospitalization. Both in-hospital and out 
of hospital deaths were included.
Person-Time
As for hospitalizations, person-time for people with diabe-
tes mellitus was estimated using the linked diabetes mellitus 
register, hospitalization, and death data. Each individual’s 
person-time was estimated as the number of days from the 
start of the study period (or date at which each person was 
diagnosed with diabetes mellitus, if this occurred during the 
study period) to the date of the incident heart failure hospital-
ization, death, or censoring at December 31, 2013 (Tables IV 
and V in the online-only Data Supplement). This was summed 
by diabetes mellitus type, calendar-year, age, sex, and depri-
vation decile. Mid-year population estimates for the general 
population in Scotland, stratified by age, sex, and deprivation, 
were obtained from National Records of Scotland. For people 
without diabetes mellitus, person-time not at risk (attributable 
to prevalent or incident heart failure events) was also summed 
by the same stratifying variables. Within the levels of these 
stratifying variables, person-time for people with no diabetes 
mellitus was obtained by subtracting the diabetes mellitus 
person-time from the midyear estimates population estimates.
Modeling
Heart failure incidence rates were estimated by age, sex, 
deprivation, calendar year, and diabetes mellitus status. 
Confidence intervals for the rate ratios and rate differences 
were obtained as per Rothman et al.11
For the main analysis, regression models were fit using 
nonparametric smooth terms (penalized thin plate regression 
splines) and interaction terms to allow for nonlinearity and 
heterogeneity respectively. We used regression in preference 
to stratification to avoid categorizing continuous variables, 
which can result in unstable estimates if a stratum is too small, 
and loss of information if a stratum is too heterogeneous.
Interactions are reported on the same scale as the main 
effects as the rate ratio (RR) or odds ratio (OR), because this can 
be interpreted as the relative difference in the magnitude of 
an association per one-unit change in the interacting variable.
For incidence rates, generalized linear models were used 
with a log-link and Poisson error distribution, using a scal-
ing factor (quasi-Poisson) to allow for overdispersion. Age in 
years was divided by 10 so that each increment was a decade 
(eg, age 44 was transformed to 4.4). Deprivation deciles were 
treated as a deprivation score ranging from 1 to 10, which 
was divided by 5 such that each increment was a 5-point 
increment. Terms were included for main effects in all models 
regardless of significance or magnitude of effect. The large 
and heterogeneous study population with a large number of 
events allowed us to investigate whether the magnitude of 
risk associated with diabetes mellitus varied by biologically 
plausible and clinically relevant variables on the basis of prior 
knowledge of diabetes mellitus and heart failure. Interaction 
terms (between 2 or more of age, sex, deprivation, and dia-
betes mellitus status) were retained if the exponentiated 
coefficient (on the transformed scale) was ≥1.05 or ≤0.95. 
However, for interactions with calendar year, all statistically 
significant interactions (at P<0.05) were included in the final 
models. Using the same covariates, generalized linear models 
with a logit-link and binomial error distribution were used to 
model both heart failure prevalence and case-fatality.
In additional analyses these models were repeated after 
excluding patients with a previous admission for ischemic 
heart disease (ICD-9 410–414 or ICD-10 I20–25), and in 
separate sensitivity analyses after adding additional ICD-10 
codes (I42.0, I42.7, I42.8, I42.9) for cardiomyopathy, and 
after restricting the analysis to admissions where heart failure 
was the primary diagnosis (recorded in the first of 6 possible 
diagnostic positions).
For the analysis of the association between the 3-year risk 
(odds) of heart failure and clinical and demographic char-
acteristics in the closed cohort, we used logistic regression 
models. Covariate missingness was addressed using multiple 
imputation (Appendix in the online-only Data Supplement). 
We fitted models for type 1 and type 2 diabetes mellitus, and 
a third model which included covariate/diabetes mellitus–
type interaction terms to compare risk factor associations 
between type 1 and type 2 diabetes mellitus. Multiple impu-
tation was used for missing data (Table IV in the online-only 
Data Supplement).
The association between heart failure and drug prescrip-
tion was not modeled because of the high likelihood of con-
founding by indication. However, we did compare the odds 
of cardiovascular medication prescription in people with type 
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2 versus type 1 diabetes mellitus. Each drug class was mod-
eled unadjusted, adjusting for age and sex, and for the risk 
of heart failure (on the logit scale) according to each per-
son’s baseline characteristics. The latter was derived from the 
model of 3-year risk in the closed cohort described above.
SPSS was used to extract the administrative data, and R 
version 3.4.3 (Vienna, Austria) was used for the statistical 
analyses.
Approval for the creation and analysis of the linked dataset 
containing no person-identifying information was obtained 
from the Scottish Care Information – Diabetes Collaboration 
(SCI-DC) steering committee, the Scottish multi-center 
research ethics committee (reference number 11/AL/0225), 
the Privacy Advisory Committee of NHS National Services 
Scotland, and Caldicott guardians.
RESULTS
This study included the entire Scottish population who 
were aged 30 or older at any time between 2004 to 
2013. In 2004, this comprised 3 066 253 people without 
a diagnosis of diabetes mellitus, 136 042 with a diagnosis 
of type 2 diabetes mellitus, and 18 240 with a diagnosis 
of type 1 diabetes mellitus. Of these, 1 642 022 (53.6%), 
63 086 (46.4%), and 8141 (44.6%), respectively, were 
women and the mean (and SD) ages were 52.9 (15.3), 
65.0 (12.2), and 50.0 (14.1) years, respectively. SIMD 
was similar across the groups with mean (SD) deprivation 
scores of 5.5 (2.9), 5.9 (2.8), and 5.6 (2.8), respectively.
Incidence of Heart Failure Hospitalization
People without diabetes mellitus (n=28 681), with type 
2 diabetes mellitus (n=3480), and with type 1 diabe-
tes mellitus (n=382) were excluded because of a previ-
ous heart failure hospitalization (Figures II and III in the 
online-only Data Supplement, Table VII in the online-
only Data Supplement). Over the 10-year period of the 
study, among the 3.25 million people remaining there 
were 91 429, 22 959, and 1313 incident heart failure 
events (during 38 112 739.9, 1 855 281.8, and 235 
924.2 person-years) among those without diabetes 
mellitus, with type 2 diabetes mellitus, and with type 1 
diabetes mellitus, respectively.
Heart failure incident hospitalization estimated rates 
from Poisson regression models adjusting for age, sex, 
and deprivation are shown in Figure 1 (and additionally 
in Figures IV and V in the online-only Data Supplement 
and in Table VIII in the online-only Data Supplement). 
For illustration, age-sex stratified rates for 2013 are 
shown in Table 1. Rates varied markedly with age and 
differed according to sex and whether or not diabetes 
mellitus was present.
Figure 1. Age-, sex-, and deprivation-adjusted incidence of heart failure hospitalization by diabetes mellitus type, age, and sex. 
The lines represent the predicted rates obtained from quasi-Poisson regression models of incident heart failure events. The ribbons are 95% confidence intervals. 
Covariates included in the model were age, sex, deprivation, and diabetes mellitus type, with interaction terms included where these improved model fit. Predic-
tions were made at the median deprivation score. Points represent event rates stratified by age (in years), sex, and diabetes mellitus type. Models are given in full in 
the Appendix in the online-only Data Supplement.
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Overall, the rate of incident heart failure hospital-
ization rose steeply with age, was somewhat higher 
in men than in women, and was higher in individuals 
with diabetes mellitus than in those without this di-
agnosis. Incident heart failure hospitalization was also 
higher in people with type 1 compared with type 2 
diabetes mellitus.
We found the relative risk of diabetes mellitus–re-
lated heart failure hospitalization (as indicated by the 
rate ratio) was highest in younger people and higher in 
women than men (Figure 1 and Table 1). However, as 
the absolute rate of incident heart failure was highest 
in older individuals, the greatest difference in absolute 
rates were also seen in these groups, and not in young-
er people and women (Figure 1).
Time Trends in Incident Heart Failure 
Hospitalization
Across the period studied, the rate of incident heart 
failure hospitalization fell slightly, at around 0.2% per 
calendar-year (RR per calendar-year 0.998; 95% CI, 
0.991–1.005).
In models adjusting for age, sex, and deprivation, 
the rate of decline was slightly steeper in older indi-
viduals. The rate of decline was 0.5% per calendar-year 
faster per 10-year increment in age (RR for interaction 
0.995; 95% CI, 0.992–0.998), and was similar in men 
and women (RR for interaction 1.006; 95% CI, 0.998–
1.014), and according to deprivation (RR for interac-
tion [per 5-point increment in deprivation score] 0.996; 
95% CI, 0.989–1.003)
From the same model, trends in heart failure inci-
dence rates in people with type 2 diabetes mellitus 
were similar to those in individuals without diabetes 
mellitus over a ten-year period from 2004 (Figure  2, 
Tables IX and X in the online-only Data Supplement). 
However, there was some evidence of a more rapid 
decline in people with type 1 diabetes mellitus, where 
the decrease was 2.2% per calendar-year faster than in 
people without diabetes mellitus.
An interactive version of Figure  2, where diabetes 
mellitus type and sex-specific temporal trends can be 
shown for patients of any age or with any level of so-
cio-economic deprivation, is available at https://ihwph-
hehta.shinyapps.io/dm_hf_fig2/.
Table 1. Incidence of Heart Failure Admissions, by Age and Sex
Age, y Sex  No Diabetes Mellitus
Type 1 Diabetes 
Mellitus 
Type 2 Diabetes 
Mellitus 
20–29 Men Rate 0.07 (26/354 377) 0.36 (1/2748) 0 (0/386)
Rate ratio — 4.96 (0.67–36.55)  
Rate difference — 0.29 (−0.42–1.00) −0.07 (−0.10–0.05)
Women Rate 0.08 (27/359 972) 0.46 (1/2162) 2.18 (1/459)
Rate ratio — 6.17 (0.84–45.38) 29.07 (3.95–213.94)
Rate difference — 0.39 (−0.52–1.29) 2.11 (−2.17–6.38)
30–49 Men Rate 0.45 (309/679 479) 1.11 (7/6304) 1.61 (23/14 260)
Rate ratio — 2.44 (1.15–5.17) 3.55 (2.32–5.42)
Rate difference — 0.66 (−0.17–1.48) 1.16 (0.50–1.82)
Women Rate 0.2 (144/721 321) 1.54 (7/4555) 1.5 (15/9984)
Rate ratio — 7.70 (3.61–16.44) 7.53 (4.42–12.81)
Rate difference — 1.34 (0.20–2.48) 1.30 (0.54–2.06)
50–69 Men Rate 2.31 (1360/587 720) 8.26 (38/4599) 6.88 (452/65 712)
Rate ratio — 3.57 (2.59–4.93) 2.97 (2.67–3.31)
Rate difference — 5.95 (3.32–8.58) 4.56 (3.92–5.21)
Women Rate 1.09 (702/645 356) 6.23 (21/3371) 5.25 (231/43 998)
Rate ratio — 5.73 (3.71–8.84) 4.83 (4.16–5.60)
Rate difference. — 5.14 (2.48–7.81) 4.16 (3.48–4.84)
70–89 Men Rate 12.68 (2832/223 396) 31.4 (27/860) 22.21 (994/44 756)
Rate ratio — 2.48 (1.70–3.62) 1.75 (1.63–1.88)
Rate difference — 18.72 (6.87–30.57) 9.53 (8.07–10.99)
Women Rate 10.26 (3361/327 652) 30.65 (31/1011) 19.75 (914/46 277)
Rate ratio — 2.99 (2.10–4.26) 1.93 (1.79–2.07)
Rate difference — 20.39 (9.60–31.19) 9.49 (8.17–10.82)
Rates and rate differences are per 1000 person-years, rate ratios and rate differences are reported with 95% confidence intervals.
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Notwithstanding any temporal decrease in absolute 
rates, the rate ratios for heart failure hospitalization 
remained large throughout the study period for both 
types of diabetes mellitus. For example, in 2013 the 
rate ratios in people with type 2 diabetes mellitus, com-
pared with those with no diabetes mellitus, were 5.81 
(95% CI, 4.91–6.86) and 3.55 (95% CI, 2.99–4.21) for 
50-year-old women and men, respectively.
Case-Fatality of Incident Heart Failure 
Hospitalization
Over the period of the study, 14.2% (16406/115701) 
of people admitted to hospital with heart failure died 
within 30 days of admission.
Thirty-day case-fatality results obtained from logistic 
regression models adjusting for age, sex, and deprivation 
are shown in Figure 3 (see the Appendix in the online-
only Data Supplement for model coefficients, including 
interactions). For illustration, age–sex stratified case-fa-
tality is shown in Table 2. Case-fatality varied markedly 
with age and differed according to sex and whether or 
not type 1 diabetes mellitus was present. It was higher in 
women than in men and in older people than in younger 
people. However, it was similar in people with type 2 dia-
betes mellitus and in people without diabetes mellitus, 
for men the OR was 0.96 (95% CI, 0.95–0.96), and for 
women the OR was 0.98 (95% CI, 0.97–0.98).
However, case-fatality was higher among people 
with type 1 diabetes mellitus compared with people 
without diabetes mellitus; the difference was larger for 
men (OR, 1.91; 95% CI, 1.68–2.18) than for women 
(OR, 1.31; 95% CI, 1.05–1.65).
Trends in case-fatality were also modeled adjust-
ing for age, sex, deprivation, calendar year, and type 
of diabetes mellitus (Figure 4, Tables XI and XII in the 
online-only Data Supplement). The rate of decline was 
around 3.3% per calendar-year (OR per calendar year, 
0.967; 95% CI, 0.961–0.974) in people without diabe-
tes mellitus. There was no evidence of a steeper decline 
in people with type 1 diabetes mellitus (OR for calendar 
year/type 2 interaction, 1.011; 95% CI, 0.959–1.065) 
or type 2 diabetes mellitus (OR for calendar year/type 2 
interaction, 0.994; 95% CI, 0.979–1.009).
Incidence of Heart Failure Hospitalization 
Without Previous Ischemic Heart Disease
Incident heart failure hospitalization was lower in peo-
ple who had never had a previous admission for isch-
Figure 2. Age-, sex-, and deprivation-adjusted trends in incident heart failure hospitalization by diabetes mellitus type, sex, and calendar-year. 
The lines represent the predicted rates obtained from generalized additive models of incident heart failure events. The ribbons are 95% confidence intervals. Co-
variates included in the model were age, sex, deprivation, diabetes mellitus type, and calendar year, with interaction terms included where these improved model 
fit. The model was fit with a log-link and Poisson likelihood, with correction of the standard errors for overdispersion. Penalized thin plate regression splines were 
used to model nonlinear associations for calendar year by diagnosis type. Predictions were made for men and women aged 50 (as this was the closest decade 
to the mean age in the general population). Models are given in full in the Appendix in the online-only Data Supplement. See https://ihwph-hehta.shinyapps.io/
dm_hf_fig2/ for an interactive version of this plot.
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emic heart disease admission (ICD-9 410–414 or ICD-
10 I20-25), with rates per 1000 person-years (py) of 1.7 
(65 657 events/38 117 663.1 py), 9.2 (17 175 events/1 
867 390.1 py), and 3.6 (841 events/236 843.7 py) for 
the no-diabetes mellitus, type 2 diabetes mellitus, and 
type 1 diabetes mellitus groups, respectively. Neverthe-
less, the rate ratios for both type 1 and type 2 diabetes 
mellitus in this group (Figures 5, Figures VI and VII in the 
online-only Data Supplement, and Tables XIII–XVI in the 
online-only Data Supplement) were similar to those in 
the whole cohort (Figure 1).
Risk Factors for Heart Failure in People 
With Diabetes Mellitus
Two hundred thousand, two hundred eight people 
with type 2 diabetes mellitus and 26,189 with type 1 
had not had a previous hospital admission with heart 
Figure 3. Age-, sex-, and deprivation-adjusted 30-day case-fatality of incident heart failure hospitalization by age, sex, and diabetes mellitus type. 
The lines represent the predicted case-fatality proportions obtained from logistic regression models of death. Covariates included in the model were age, sex, 
deprivation, and diabetes mellitus type, with interaction terms included where these improved model fit. Predictions were made at the median deprivation score. 
Points represent case-fatality proportions stratified by age, sex, and diabetes mellitus type, with the point size being proportional to the number in the denomina-
tor. Models are given in full in the Appendix in the online-only Data Supplement.
Table 2. Thirty-Day Case-Fatality of Incident Heart Failure Hospitalization, by Age and Sex
Age, y Sex No Diabetes Mellitus
Type 1 Diabetes 
Mellitus Type 2 Diabetes Mellitus
20–39 Men 4.0 (8/199) 10.0 (1/10) 0.0 (0/4)
Women 4.6 (6/130) 0.0 (0/7) 0.0 (0/5)
30–49 Men 4.4 (131/2953) 9.3 (10/107) 3.1 (8/258)
Women 7.8 (97/1248) 8.8 (6/68) 6.2 (8/129)
50–69 Men 6.9 (974/14 175) 13.6 (43/316) 7.3 (305/4151)
Women 10.0 (721/7242) 10.6 (25/236) 9.4 (196/2082)
70–89 Men 16.5 (4795/29 013) 23.0 (63/274) 14.6 (1216/8318)
Women 17.7 (6462/36 469) 18.3 (54/295) 15.9 (1277/8012)
All Men 12.7 (5908/46 340) 16.5 (117/707) 12.0 (1529/12 731)
Women 16.2 (7286/45 089) 14.0 (85/606) 14.5 (1481/10 228)
Case-fatality shown as percentages (deaths/admissions).
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failure on October 1, 2013. In this cohort, over 3 years 
of follow-up the risk of heart failure was 6752 (2.3%) 
and 231 (0.9%) for type 2 and type 1 diabetes mel-
litus, respectively.
Age, sex, body mass index, estimated glomerular fil-
tration rate, smoking, previous ischemic heart disease, 
and stroke all predicted an increased risk of heart fail-
ure, although no associations were found for systolic 
blood pressure, total cholesterol, or HDL cholesterol 
(Table 3). After adjusting for conventional risk factors, 
longer duration of diabetes mellitus and higher concen-
trations of hemoglobin A1c also predicted heart failure 
risk. Of note, there was no evidence that any of the 
predictors of heart failure differed between type 1 and 
type 2 diabetes mellitus.
People with type 2 diabetes mellitus were more likely 
than those with type 1 diabetes mellitus to have a cur-
rent prescription for a range of cardiovascular drugs (Ta-
ble 4). Across all drug-classes examined, compared with 
people with type 1 diabetes mellitus, those with type 
2 diabetes mellitus were more likely to have been pre-
scribed cardiovascular medications. For loop diuretics 
and antiplatelets the risk was not higher after adjusting 
for age and sex (OR, 0.87; 95% CI, 0.82 to 0.93 and 
OR, 1.03; 95% CI, 0.99 to 1.07, respectively). However, 
for the remaining cardiovascular drug classes (includ-
ing lipid lowering drugs, drugs acting on the renin-an-
giotensin system and calcium channel blockers) higher 
prescription levels in type 2 diabetes mellitus persisted 
on adjusting for age and sex, and on adjusting for the 
predicted risk of heart failure (Table 4).
Sensitivity Analyses
On restricting incident heart failure admissions to those 
where heart failure was the primary diagnosis, the 
heart failure incidence rates were around half of those 
reported for any incident admission, with rates per 
1000 person-years (py) of 0.9 (34 893 events/38 080 
361.9 py), 6.1 (11 551 events/1 885 715.8 py), and 2.7 
(635 events/237 683.5 py) for the no-diabetes mellitus, 
type 2 diabetes mellitus, and type 1 diabetes mellitus 
groups respectively. Nonetheless, compared with the 
main analysis (Figure 1, Figures IV and V in the online-
only Data Supplement, and Table VII in the online-only 
Data Supplement) similar associations were found (Fig-
ures VIII and IX in the online-only Data Supplement and 
Tables XVII–XIX in the online-only Data Supplement). 
On adding cardiomyopathy codes (I42.0, I42.7, I42.8, 
I42.9) to the heart failure definition used in the main 
analysis, similar results were also found; this was true 
for the absolute incident rates and case-fatality, and the 
rate ratios and odds ratio comparing the 3 groups (type 
1, type 2 and no diabetes mellitus).
Figure 4. Age-, sex-, and deprivation-adjusted trends in 30-day case-fatality of incident heart failure hospitalization. 
The lines represent the predicted rates obtained from generalized additive models of heart failure 30-day case-fatality on age, sex, deprivation, diabetes mellitus type, 
and calendar year, with interaction terms included where these improved model fit, using a logit-link and binomial likelihood. Predictions were made for men and wom-
en aged 50 (as this was the closest decade to the mean age in the general population). Models are given in full in the Appendix in the online-only Data Supplement.D
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On comparing the clinician-recorded and corrected 
clinician-recorded definitions of diabetes mellitus type 
in the closed cohort, similar associations between type 
of diabetes mellitus and 3-year risk of heart failure were 
found; adjusting for age, sex, and deprivation, the ORs 
were 1.24 (95% CI, 1.09–1.40) and 1.21 (95% CI, 
1.05–1.38), respectively.
DISCUSSION
We documented the rate of incident heart failure hos-
pitalizations in a large and complete national dataset 
which included >250 000 people with diabetes mellitus 
among a population of >3.25 million people aged ≥30 
years, in whom there were >115 000 first hospitaliza-
tions for heart failure.
We examined trends in these rates, and the associated 
30-day case-fatality, over a 10-year period (2004–2013). 
Importantly, we reported these rates and trends sepa-
rately for people with type 1 and type 2 diabetes mellitus.
We found that the age- and sex-adjusted rates of 
incident heart failure hospitalization were ≈2-fold high-
er in people with diabetes mellitus, regardless of type, 
compared with those without diabetes mellitus. In all 
groups, there was a decline in incidence rate of ≈2% 
over the decade studied, with a slightly greater rate of 
decline in people with type 1 diabetes mellitus than in 
the other groups studied.
In terms of trends, heart failure incident hospitaliza-
tion appears to be falling more quickly over time (both 
in absolute and proportional terms) in people with type 
1 diabetes mellitus, compared with people with type 
2 diabetes mellitus and with people without diabetes 
mellitus. The difference was moderate; having adjusted 
for age, sex, and deprivation, the decline was faster in 
those with type 1 diabetes mellitus (2.1% per year ver-
sus 0.2% per year). We are not aware that this finding 
has been reported previously, but it is consistent with 
an observation from the Swedish registry that the rate 
ratio for type 1 diabetes mellitus and incident heart fail-
ure was larger in the 1998 to 2004 period than in the 
2005 to 2011 period.2
We also found that the relative difference in heart 
failure incidence between people without diabetes mel-
litus and those with type 1 or type 2 diabetes mellitus 
was larger for younger people and for women than for 
older people and men. This is consistent with previous 
reports.1–3 It is important to note, however, that because 
of the higher overall rates in men and older people, 
the absolute differences in heart failure incidence were 
Figure 5. Age-, sex-, and deprivation-adjusted incidence of heart failure hospitalization by diabetes mellitus type, age, and sex in people without 
previous ischemic heart disease. 
The lines represent the predicted rates obtained from quasi-Poisson regression models of incident heart failure events. The ribbons are 95% confidence intervals. 
Covariates included in the model were age, sex, deprivation, and diabetes mellitus type, with interaction terms included where these improved model fit. Predic-
tions were made at the median deprivation score. Points represent event rates stratified by age (in years), sex, and diabetes mellitus type. Models are given in full in 
the Appendix in the online-only Data Supplement.
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larger in these groups. Therefore, from the perspective 
of the individual patient, the impact of diabetes mel-
litus on heart failure risk is greater at older ages and in 
men. Indeed, the absolute difference in 1-year risk of 
heart failure admission in 80-year-old men (the group 
with the smallest relative difference) with and without 
diabetes mellitus was 2.5%. For the same comparison, 
but in 40-year-old women, the difference was <0.5%.
Unlike incidence, for case-fatality the relationship 
with diabetes mellitus depended on the type of diabetes 
mellitus. Case-fatality was similar among people with 
type 2 diabetes mellitus compared with those without 
diabetes mellitus. However, among people with type 1 
diabetes mellitus, case-fatality was 1.3-fold higher in 
women and 1.9-fold higher in men.
Women therefore have a 2-fold higher heart failure 
incidence and a 1.3-fold higher case-fatality. In combi-
nation, this means that compared with women without 
diabetes mellitus, women with type 1 diabetes mellitus 
have around a 2.5-fold higher risk of having an incident 
heart failure admission which results in death within 30 
days. For the equivalent comparison in men, there is 
almost a 4-fold difference in risk.
Elevated incidence rates for heart failure admission 
among people with type 2 diabetes mellitus have been 
reported previously. One study using the Clinical Practice 
Research Database (CPRD) used primary care records to 
define heart failure and type 2 diabetes mellitus. The 
authors identified 34 198 people with type 2 diabe-
tes mellitus from 1998 to 2010. Among women >60 
years of age with and without type 2 diabetes mellitus, 
they found a relative difference (hazard ratio) of 1.50.3 
We obtained a similar relative difference (rate ratio) of 
2.12 (95% CI, 2.06–2.17). For men >60 years of age, 
the comparable figures were 1.43 and 1.93 (95% CI, 
1.88–1.98), respectively. The fact that we included only 
hospitalizations, and not primary care attendances, may 
account for the slightly stronger associations we report.
In the international Reduction of Atherothrombosis 
for Continued Health (REACH) registry, there was also 
an elevated risk of heart failure hospitalization among 
the 19 699 people with diabetes mellitus (type unspeci-
Table 3. Risk Factors for Heart Failure in People With Diabetes Mellitus: Summary Statistics, Association With Incident Heart Failure 
Hospitalization Within Three Years, and Comparison of Association in Type 1 Versus Type 2 Diabetes Mellitus
Risk Factor Summary Statistics Heart Failure Risk Factors Stratified
Heart Failure Risk Factors 
Comparison
 Type 1 Type 2 Type 1 Type 2 Type 1/Type 2 P Value
N 26 189 288 208     
Age, y 45 (15) 65 (13) 1.85 (1.57–2.19) 1.99 (1.91–2.07) 0.93 (0.78–1.11) 0.42
Male 14 907 (56.9%) 162 029 (56.2%) 1.05 (0.79–1.40) 1.16 (1.09–1.22) 0.91 (0.68–1.22) 0.52
Deprivation (deciles) 5 (3 to 8) 5 (3 to 7) 1.14 (0.99–1.32) 1.10 (1.06–1.12) 1.04 (0.90–1.20) 0.57
Body mass index, kg/m2 26 (24 to 30) 31 (28 to 35) 1.22 (1.04–1.45) 1.26 (1.23–1.30) 0.97 (0.82–1.15) 0.74
Never smoker 13 047 (54.7%) 113 952 (43.6%) 1 1 1 —
Ex-smoker 4510 (18.9%) 92 826 (35.5%) 1.91 (1.38–2.63) 1.22 (1.15–1.30) 1.56 (1.12–2.16) 0.008
Current smoker 6297 (26.4%) 54 874 (21%) 2.04 (1.42–2.93) 1.59 (1.48–1.71) 1.28 (0.88–1.86) 0.20
Systolic blood pressure, mm Hg 130 (13) 136 (13) 1.06 (0.93–1.20) 1.08 (1.05–1.11) 0.98 (0.86–1.11) 0.73
Diastolic blood pressure, mm Hg 75 (8) 77 (8) — — — —
Total cholesterol, mg/dL 4.7 (1) 4.4 (1) 1.30 (1.15–1.48) 0.99 (0.96–1.02) 1.32 (1.16–1.51) <0.001
LDL cholesterol, mg/dL 2.5 (0.8) 2.3 (0.9) — — — —
HDL cholesterol, mg/dL 1.5 (0.4) 1.2 (0.3) 0.90 (0.79–1.02) 1.00 (0.97–1.03) 0.90 (0.79–1.02) 0.10
HbA1c, mmol/mol 71 (62 to 83) 56 (48 to 67) 1.32 (1.16–1.51) 1.17 (1.13–1.20) 1.13 (0.99–1.29) 0.06
Estimated glomerular filtration 
rate, mL/min
98 (83 to 110) 81 (65 to 93) 0.65 (0.56–0.75) 0.72 (0.70–0.74) 0.90 (0.77–1.05) 0.17
Previous stroke 275 (29.3%) 7278 (26.7%) 1.93 (1.09–3.40) 1.36 (1.21–1.52) 1.42 (0.80–2.53) 0.24
Previous myocardial infarction 585 (62.4%) 18 224 (66.7%) 1.60 (1.03–2.49) 1.68 (1.56–1.80) 0.96 (0.61–1.50) 0.84
Duration of diabetes mellitus, y 19 (10 to 30) 5 (1 to 11) 1.29 (1.18–1.40) 1.17 (1.14–1.20) 1.10 (1.01–1.20) 0.04
Retinopathy 7900 (30.2%) 36 410 (12.6%) 0.66 (0.48–0.92) 1.15 (1.07–1.23) 0.58 (0.41–0.80) 0.001
Summary statistics are the number (percentage), mean (standard deviation), and median (interquartile range) for risk factors which are categorical, 
symmetrical, and skewed continuous variables, respectively. The odds ratios (and 95% confidence intervals) are for the odds of heart failure within 3 years for 
people with type 1 and type 2 diabetes mellitus, along with an interaction odds ratio for the difference in odds ratio between people with type 1 and type 2 
diabetes mellitus. The P value for the interaction is also shown. Deprivation is coded from least to most deprived. All continuous variables were standardized so 
that the odds ratio can be interpreted as the increase in odds per standard deviation increment. All variables in the table were included in the model with the 
exception of LDL cholesterol because this was not measured in large proportion of patients, and diastolic blood pressure because this is likely to be collinear 
with systolic blood pressure. The extent of missing data and approach to missingness are documented in the Appendix in the online-only Data Supplement.
HbA1C indicates hemoglobin A1c; HDL, high-density lipoprotein; and LDL, low-density lipoprotein. 
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fied) compared to people without diabetes mellitus.1 
However, the magnitude of the association in this co-
hort, which mainly included people with established 
atherothrombotic disease or risk factors for athero-
thrombosis, was weaker than we found at 1.33-fold. In 
sensitivity analyses excluding any patient with a previ-
ous ischemic heart disease admission, we continued to 
observe an ≈2-fold association. However, we did not 
have any measures of stable coronary disease. As such, 
one explanation for the stronger association we ob-
served is that the increased heart failure risk in diabetes 
mellitus is partly related explained through increased 
risk of atheromatous disease.
Previous studies examining case-fatality after heart 
failure admissions among people with type 2 diabetes 
mellitus have been equivocal. One multi-center reg-
ister study found no difference in in-hospital mortal-
ity among people with diabetes mellitus compared 
to those without (OR, 1.00; 95% CI, 0.88–1.14).12 
Similarly, in a study in the Scottish population com-
paring incident heart failure admissions from 1986 to 
2003, the age–sex adjusted 30-day case-fatality fol-
lowing heart failure admission was lower in people 
with diabetes mellitus than in those without diabetes 
mellitus (for example in men aged 65–74 the OR was 
0.82; 95% CI, 0.73–0.93), although case-fatality at 
1 year was higher.13 Neither study, however, included 
data on diabetes mellitus type. Because the majority 
of people with diabetes mellitus have type 2 diabetes 
mellitus, these reports are consistent with our own 
finding that people with type 2 diabetes mellitus did 
not have a higher case-fatality than individuals with-
out diabetes mellitus.
Fewer studies have examined heart failure as a com-
plication of type 1 diabetes mellitus. The largest, which 
was a population-based study from Sweden, and which 
updates and extends a previous report from the same 
diabetes mellitus registry,14 reported a rate of incident 
heart failure hospitalization of 6.7 per 1000 person-
years in people with type 1 diabetes mellitus compared 
to 4.0 per 1000 person-years in individuals without dia-
betes mellitus, similar to the difference we observed.2 
However, those investigators did not examine trends 
over time or case-fatality. Indeed, ours is the first pop-
ulation-based study of which we are aware to compare 
case-fatality after heart failure admissions in people 
with and without type 1 diabetes mellitus, and we are 
not aware that the high case-fatality in patients with 
type 1 diabetes mellitus has been reported previously.
The mechanisms underlying this difference in case-
fatality are unknown, and mechanistic studies are need-
ed. Indeed, excepting coronary artery atherosclerosis, 
the mechanisms underlying the relationship between 
diabetes mellitus and heart failure are not well under-
stood, and whether or not diabetic cardiomyopathy 
represents a distinct entity remains controversial.15–17 
Notwithstanding the mechanisms, however, the in-
creased case-fatality provides additional support for the 
view that heart failure is an under-recognized and im-
portant complication in type 1 diabetes mellitus.18
Time trends in case-fatality were similar across 
groups. For people with and without diabetes mellitus, 
regardless of type, we found that case-fatality fell by 
around 3% per-year. We were unable to identify any 
previous study which compared heart failure admission 
case-fatality trends among people with and without 
Table 4. Cardiovascular Drugs in People With Diabetes Mellitus
 Summary Statistics Odds Ratio for Drug Prescription in Type 2 Versus Type 1
Drug Type 1 Type 2 Unadjusted Model 1 Model 2
Thiazides 1349 (5.2) 47 228 (16.4) 3.61 (3.41–3.82) 2.17 (2.04–2.29) 2.11 (1.99–2.23)
Loop diuretics 1174 (4.5) 31 623 (11.0) 2.63 (2.47–2.79) 0.87 (0.82–0.93) 0.88 (0.82–0.94)
Potassium sparing diuretics 197 (0.8) 7055 (2.4) 3.31 (2.87–3.82) 1.78 (1.53–2.05) 1.68 (1.45–1.94)
Beta blockers 1996 (7.6) 75 105 (26.1) 4.27 (4.08–4.47) 2.15 (2.05–2.25) 1.97 (1.88–2.07)
Renin–angiotensin system 
drugs
7563 (28.9) 145 304 (50.4) 2.50 (2.44–2.57) 1.33 (1.29–1.37) 1.14 (1.10–1.17)
Nitrates and other 
antianginal drugs
653 (2.5) 24 183 (8.4) 3.58 (3.31–3.88) 1.55 (1.43–1.68) 1.50 (1.38–1.63)
Calcium-channel blockers 2637 (10.1) 72 817 (25.3) 3.02 (2.90–3.15) 1.59 (1.52–1.66) 1.48 (1.41–1.54)
Anticoagulants 249 (1) 14 386 (5) 5.47 (4.83–6.21) 1.82 (1.60–2.07) 1.74 (1.53–1.98)
Antiplatelets 4079 (15.6) 94 631 (32.8) 2.65 (2.56–2.74) 1.03 (0.99–1.07) 0.90 (0.87–0.94)
Lipid-lowering drugs 9222 (35.2) 178 100 (61.8) 2.98 (2.90–3.06) 1.39 (1.35–1.43) 1.21 (1.18–1.25)
N (%) of people currently prescribed ≥1 drug the relevant class at the start of the closed cohort, October 1, 2013. Odds ratios (95% CIs) 
that drug is prescribed in people with type 2 versus type 1 diabetes mellitus. Each drug-class was modeled separately, unadjusted, adjusted 
for age and sex (model 1), and adjusted for the predicted risk of heart failure (model 2). The predicted risk in model 2 was obtained from 
the full set of model coefficients for the full models shown in Table 3, and hence is based on each patient’s baseline characteristics (age, sex, 
deprivation, duration of diabetes mellitus, body mass index, smoking status, previous stroke, previous myocardial infarction, systolic blood 
pressure total and high-density cholesterol, hemoglobin A1c, estimated glomerular filtration rate, and retinopathy). See the Appendix in the 
online-only Data Supplement for the approach used to classify drugs.
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diabetes mellitus. Nonetheless, similar trends have been 
reported in unselected patients, and in people with type 
2 diabetes mellitus. In terms of the former, a study using 
the Swedish national hospital discharge register, which 
included 13.6% of people with type 2 diabetes mellitus, 
found a decline of ≈4% per-year (hazard ratio 0.96 per 
year during the 5-year period from 1987–2006).19 Also, 
trends after heart failure admissions were examined for 
people with type 2 diabetes mellitus in a subset of the 
U.S. National Inpatient Sample mortality (defined us-
ing administrative data – ICD-9-CM codes 250.0–250.9 
with a fifth digit of 0 or 2). In models adjusting for age 
and sex, case-fatality fell by ≈5% per year from 2000 to 
2010.20 This is consistent, therefore, with our findings.
In the general adult population, a number of risk 
factors such as age, sex, deprivation, smoking, obesity, 
hypertension, cholesterol, and previous cardiovascular 
disease are known to predict heart failure.21 Lind et al14 
also showed that, among people with type 1 diabetes 
mellitus, smoking, systolic blood pressure, high body 
mass index, duration of diabetes mellitus, and hemo-
globin A1c were associated with increased heart failure 
incidence. We obtained similar findings for the associa-
tion between these risk factors and the 3-year risk of 
heart failure among people with type 1 diabetes mel-
litus. We have also been able to show that very similar 
associations (both in terms of magnitude and direction) 
are evident for people with type 2 as well as type 1 
diabetes mellitus.
We also found that people with type 1 diabetes 
mellitus were less commonly prescribed drugs known 
to reduce the risk of heart failure (whether directly or 
through reducing the risk of heart disease); this includ-
ed antihypertensives, drugs acting on the renin–angio-
tensin, system and lipid-lowering drugs.22 Importantly, 
these differences were still found after taking into ac-
count the fact that people with type 2 diabetes mellitus 
are older, and even after adjusting for each patient’s 
predicted risk of heart failure (based on their baseline 
characteristics). Considerable caution is needed in in-
terpreting this finding, as the clinical risk factors (blood 
pressure, smoking, etc) used to adjust for baseline risk 
were obtained as part of routine clinical care, not in a 
prospective study, and were not available for some pa-
tients. Nonetheless, this observation does raise the pos-
sibility that, even where the heart failure risk is similar, 
people with type 1 diabetes mellitus may be less likely 
than people with type 2 diabetes mellitus to receive 
preventative drug therapy.
The strengths of our study include the very large 
population-based nature of the electronic record of di-
agnosed diabetes mellitus that captures data for >99% 
of the population of Scotland, information on the type 
of diabetes mellitus, and the availability of linkage to 
quality-assured hospital admission and mortality data 
for the whole population.23 A limitation is that heart 
failure events insufficiently severe to require admission 
to hospital were not captured as we did not have access 
to primary care data.
However, we have previously shown via review by 
2 independent clinicians (a generalist and cardiologist) 
that heart failure admissions in the Scottish hospitaliza-
tion database are reliably recorded.24 Moreover, similar 
associations were found in a sensitivity analysis which 
restricted the definition of heart failure to admission 
where this was coded in the first diagnostic position.
Secondly, although the data were of high quality, 
some misclassification as a result of diagnostic uncer-
tainty is likely to have occurred. In particular, some peo-
ple with type 1 diabetes mellitus will have been classi-
fied as type 2 diabetes mellitus, and vice versa. However, 
there is no reason to suppose that this misclassification 
will have been differential by outcome, and it is there-
fore likely to have attenuated any observed differences 
between type 1 and type 2 diabetes mellitus. Indeed, in 
the cohort restricted to patients with diabetes mellitus 
in 2013, the use of a more precise definition of diabetes 
mellitus type did not importantly affect the estimated 
3-year risk of diabetes mellitus. A further limitation is 
that we did not have accurate data on race or ethnicity, 
and so we cannot comment on whether associations 
between diabetes mellitus and heart failure incidence 
differ by these variables.
Finally, we did not have access to sufficient data on 
left ventricular function to comment on the relative 
contribution of reduced and preserved ejection fraction 
heart failure on the differences between people with 
and without diabetes mellitus.
Conclusion
Despite falling incidence rates, particularly in type 1 
diabetes mellitus, heart failure remains ≈2-fold higher 
than in people without diabetes mellitus, with case-
fatality also being higher in people with type 1 diabetes 
mellitus. Those with type 1 diabetes mellitus also re-
ceived fewer preventative cardiovascular medications. 
These findings provide additional support for the view 
that heart failure is an under-recognized and important 
complication in diabetes mellitus, particularly among 
people with type 1 diabetes mellitus.
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